Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) will be releasing its earnings data after the market closes on Tuesday, November 12th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Lexicon Pharmaceuticals Stock Up 1.7 %

Shares of LXRX traded up $0.02 during trading on Wednesday, reaching $1.21. The company's stock had a trading volume of 2,595,547 shares, compared to its average volume of 3,482,319. The company has a fifty day moving average of $1.69 and a two-hundred day moving average of $1.76. Lexicon Pharmaceuticals has a twelve month low of $0.92 and a twelve month high of $3.73. The company has a market cap of $297.95 million, a price-to-earnings ratio of -1.54 and a beta of 1.24. The company has a quick ratio of 11.49, a current ratio of 11.51 and a debt-to-equity ratio of 0.41.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LXRX. StockNews.com raised Lexicon Pharmaceuticals to a "sell" rating in a research report on Tuesday, July 9th. HC Wainwright reissued a "buy" rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a research report on Tuesday. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 30th. Finally, Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the company an "outperform" rating in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Lexicon Pharmaceuticals has an average rating of "Hold" and an average price target of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.